Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 47.06 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $1.034 million which beat the analyst consensus estimate of $442.000 thousand by 133.94 percent. This is a 82.69 percent increase over sales of $566.000 thousand the same period last year.